Potent in vivo antiangiogenic effects of GS-101 (5′- TATCCGGAGGGCTCGCCATGCTGCT-3′), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 2, 2009, Pages 496-504

  Al Mahmood, Salman ^a,e   Colin, Sylvie ^a   Farhat, Nada ^b   Thorin, Eric ^b   Steverlynck, Celine ^a   Chemtob, Sylvain ^c,d  

^a Parc Scientifique de Luminy   (France)

^b MONTREAL HEART INSTITUTE   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

^e Gene Signal Laboratories   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5' THREONYLALANYLTHREONYLCYSTEINYLCYSTEINYLGLYCYLGLYCYLALANYLGLYCYLGLYCYL GLYCYLCYSTEINYLTHREONYLCYSTEINYLGLYCYLCYSTEINYLCYSTEINYLALANYLTHREONYL GLYCYLCYSTEINYLTHREONYLGLYCYLCYSTEINYLTHREONYL 3'; ANTISENSE OLIGONUCLEOTIDE; GS 101; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; OLIGONUCLEOTIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORNEA; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG INHIBITION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TISSUE LEVEL; ANIMAL; BIOSYNTHESIS; CHEMISTRY; CORNEA NEOVASCULARIZATION; CULTURE TECHNIQUE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; LEWIS RAT; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL CULTURE TECHNIQUES; CORNEAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MALE; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, INBRED LEW; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 65649108417     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.147496     Document Type: Article

References (37)

1. Amano S, Rohan R, Kuroki M, Tolentino M, and Adamis AP (1998) Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39:18-22.
2. Andrieu-Soler C, Berdugo M, Doat M, Courtois Y, BenEzra D, and Behar-Cohen F (2005) Downregulation of IRS-1 expression causes inhibition of corneal angiogen-esis. Invest Ophthalmol Vis Sci 46:4072-4078.
3. Araki E, Lipes MA, Patti ME, Brüning JC, Haag B 3rd, Johnson RS, and Kahn CR (1994) Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372:186-190.
4. BenEzra D, Hemo I, and Maftzir G (1990) In vivo angiogenic activity of interleukins. Arch Ophthalmol 108:573-576.
5. Bock F, Kònig Y, Kruse F, Baier M, and Cursiefen C (2008a) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246:281-284.
6. Bock F, Onderka J, Dietrich T, Bachmann B, Pytowski B, and Cursiefen C (2008b) Blockade of VEGFR3-signailing specifically inhibits lymphangiogenesis in inflammatory corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246:115-119.
7. Bullard LE, Qi X, and Penn JS (2003) Role for extracellular signal-responsive kinase-1 and -2 in retinal angiogenesis. Invest Ophthalmol Vis Sci 44:1722-1731.
8. Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, Ehler E, Kakkar W, Stalmans I, Mattot V, et al. (1999) Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 5:495-502.
9. Coster DJ and Williams KA (2003) Management of high-risk corneal grafts. Eye 17:996-1002.
10. Delafontaine P, Song YH, and Li Y (2004) Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vase Biol 24:435-444.
11. Fantin VR, Wang Q, Lienhard GE, and Keller SR (2000) Mice lacking insulin receptor substrate 4 exhibit mild defects in growth, reproduction, and glucose homeostasis. Am J Physiol Endocrinol Metab 278:EI27-EI33.
12. Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, and Kleinman HK (1989) Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58:933-943.
13. Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
14. Jaffe EA, Nachman RL, Becker CG, and Minick CR (1973) Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest 52:2745-2756.
15. Jiang ZY, He Z, King BL, Kuroki T, Opland DM, Suzuma K, Suzuma I, Ueki K, Kulkarni RN, Kahn CR, et al. (2003) Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J Biol Chem 278:31964-31971.
16. Liang L, Zhou T, Jiang J, Pierce JH, Gustafson TA, and Frank SJ (1999) Insulin receptor substrate-1 enhances growth hormone-induced proliferation. Endocrinology 140:1972-1983.
17. Liu SC, Wang Q, Lienhard GE, and Keller SR (1999) Insulin receptor substrate 3 is not essential for growth or glucose homeostasis. J Biol Chem 274:18093-18099.
18. Miele C, Rochford JJ, Filippa N, Giorgetti-Peraldi S, and Van Obberghen E (2000) Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem 275:21695-21702.
19. Mwaikambo BR, Sennlaub F, Ong H, Chemtob S, and Hardy P (2006) Activation of CD36 inhibits and induces regression of inflammatory corneal neovascularization. Invest Ophthalmol Vis Sci 47:4356-4364.
20. Panda A, Vanathi M, Kumar A, Dash Y, and Priya S (2007) Corneal graft rejection. Surv Ophthalmol 52:375-396.
21. Sainson RC, Johnston DA, Chu HC, Holderfield MT, Nakatsu MN, Crampton SP, Davis J, Conn E, and Hughes CC (2008) TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood 111:4997-5007.
22. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, and D'Amore PA (2008) Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS ONE 3:e3554.
23. Salman A-M (2000), inventor; Gene Signal International SA, assignee. Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use of thereof for therapeutic purposes. U.S. patent US6716585. 2004 June 4.
24. Salman A-M (2002a), inventor; Gene Signal International SA, assignee. Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells. U.S. patent application CA2451874.
25. Salman A-M (2002b), inventor; Gene Signal International SA, assignee. Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells. U.S. patent application EP1409672.
26. Salman A-M (2002c), inventor; Gene Signal International SA, assignee. Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells. U.S. patent US7417033. 2008 Aug 26.
27. Salman A-M, Colin S, and Schneider C (2003), inventors; Gene Signal International SA, assignee. Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof. U.S. patent application EP1566387.
28. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P, Warot XM, Rio C, et al. (2003) Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 23:7084-7092.
29. Senthil D, Ghosh Choudhury G, Bhandari BK, and Kasinath BS (2002) The type 2 vascular endothelial growth factor receptor recruits insulin receptor substrate-1 in its signalling pathway. Biochem J 368:49-56.
30. Shaw LM (2001) Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phos-phoinositide 3-OH kinase and promotion of invasion. Mol Cell Biol 21:5082-5093.
31. Shein NA, Tsenter J, Alexandrovich AG, Horowitz M, and Shohami E (2007) Akt phosphorylation is required for heat acclimation-induced neuroprotection. J Neu-rochem 103:1523-1529.
32. Slomiany MG and Rosenzweig SA (2004) IGF-1-induced VEGF and IGFBP-3 secretion correlates with increased HIF-1 alpha expression and activity in retinal pigment epithelial cell line D4O7. Invest Ophthalmol Vis Sci 45:2838-2847.
33. Voghel G, Thorin-Trescases N, Farhat N, Mamarbachi AM, Villeneuve L, Fortier A, Perrault LP, Carrier M, and Thorin E (2008) Chronic treatment with N-acetyl-cystein delays cellular senescence in endothelial cells isolated from a subgroup of atherosclerotic patients. Mech Ageing Dev 129:261-270.
34. White MF (1998) The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Recent Prog Horm Res 53:119-138.
35. White MF (2002) IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283:E4I3-E422.
36. Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, and White MF (1999) Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat Genet 23:32-40.
37. Yamada J, Dana MR, Sotozono C, and Kinoshita S (2003) Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury. Exp Eye Res 76:161-167.